Onward Medical N.V.

Regulatory Filings • Apr 7, 2022

ONWARD Medical's Parkinson's Therapy Published in New England Journal of Medicine

ONWARD's Innovative Approach to Treating Hypotension for Spinal Cord Injury may also apply to Neurodegenerative Conditions

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland—April 7, 2022–ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces an important publication in the New England Journal of Medicine (NEJM), highlighting the use of ONWARD's innovative approach to treating orthostatic hypotension in a patient with MSA-P, a degenerative nervous system disease.

Today's NEJM paper detailed research conducted by NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and the Centre Hospitalier Universitaire Vaudois (CHUV), which is co-led by Professor Grégoire Courtine, PhD and Neurosurgeon Jocelyne Bloch, MD. Professor Courtine and Dr. Bloch co-authored the paper, entitled, "Implanted System for Orthostatic Hypotension in Multiple System Atrophy".

The paper presents a 48 year-old patient suffering from MSA-P, a form of Parkinson's disease that affects the sympathetic nervous system. Severe orthostatic hypotension (low blood pressure) left this patient bedridden and unable to walk or stand for more than eighteen months. Following implant of a system that stimulates the spinal cord, the patient can now walk more than 250 meters. The NEJM paper includes an animation that describes this new approach and its impact on the patient.

This implant technique has already been used by ONWARD's research collaborators at NeuroRestore to treat orthostatic hypotension in people with spinal cord injury (SCI), but this is the first time the approach has been shown to improve the quality of life in a person suffering from a neurodegenerative disease. Both SCI and neurodegenerative diseases such as Parkinson's can result in orthostatic hypotension, a condition that results in sharp drops in blood pressure particularly during changes in body position, such as transitioning from lying down to sitting or standing. Because current treatment options are inadequate, this has a significant negative impact on quality of life, as people are forced to lie down to avoid loss of consciousness.

While ONWARD is currently focused on developing and commercializing therapies for people with spinal cord injury, it expects to use its IP, technology, and other resources to develop similar therapies for people with MSA-P and other forms of Parkinson's disease. In March 2022, the company announced it had acquired the IP rights to develop and commercialize spinal cord stimulation therapies for Parkinson's disease from EPFL and CHUV.

"Professor Courtine and Dr. Bloch have demonstrated a remarkable breakthrough in addressing orthostatic hypotension and enabling the ability to stand and walk again, even in a person with severe Parkinson's disease," said Dave Marver, CEO of ONWARD. "While ONWARD is working hard to commercialize therapies for the SCI community in 2023, our future pipeline also includes very promising therapies for Parkinson's and other movement related disorders."

To learn more about ONWARD's ARC Therapy and the company's vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com.

About ONWARD

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD's work builds on more than a decade of basic science and preclinical research conducted at the world's leading neuroscience laboratories. ONWARD's ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company's first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains a significant team in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.

For Media Enquiries: media@onwd.com +44 (0) 7884 496 251

For Investor Enquiries: investors@onwd.com

For Company Enquiries: ONWARD – info@onwd.com

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the

Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.